Pramod Thomas is a senior correspondent with Asian Media Group since 2020, bringing 19 years of journalism experience across business, politics, sports, communities, and international relations. His career spans both traditional and digital media platforms, with eight years specifically focused on digital journalism. This blend of experience positions him well to navigate the evolving media landscape and deliver content across various formats. He has worked with national and international media organisations, giving him a broad perspective on global news trends and reporting standards.
PORT and logistics firm DP World has paused a £1 billion investment in Britain after ministers criticised practices at its subsidiary P&O Ferries, Sky News reported, in a blow to the government before an investment summit.
Prime minister Keir Starmer is hoping to use Monday's (14) international investment summit to pitch his goals of generating growth and providing stability that companies need to invest.
But his government's "pro-business, pro-worker" initiative faces a stern test after criticism of P&O Ferries by deputy prime minister Angela Rayner and transport minister Louise Haigh appeared to disrupt preparations for the summit.
Dubai-based DP World is reviewing the planned investment that had been due to be a major plank of Monday's summit announcements, Sky News and Bloomberg reported. The reports also said DP World's chairman, Sultan Ahmed bin Sulayem, had pulled out of his planned attendance at the summit.
DP World declined to comment on the reports.
In 2022, Britain's P&O Ferries made 800 staff redundant with immediate effect and suspended crossings for the next few days, prompting a backlash from politicians and unions who criticised plans to hire cheaper agency workers instead.
Angela Rayner. (Photo: Getty Images)
P&O Ferries at the time said it had to make swift and significant changes because the business was not sustainable otherwise.
This week, Rayner and Haigh announced new protections for seafarers, and ended what they said was a loophole used by P&O Ferries. Rayner said the government was on a mission "so no employer can abuse the system", while Haigh said the mass sackings were a "national scandal".
In an interview with ITV News, Haigh called P&O Ferries a "rogue operator" and said she had been boycotting them for years.
Asked by broadcasters about DP World's decision to pull the investment as a result of the remarks by ministers, Starmer declined to comment, and pointed to a raft of other investments announced by the government in the run-up to the summit.
In a statement in response to the report, a spokesperson for the government said it welcomed "P&O Ferries' commitment to comply with our new seafarers' legislation".
"We continue to work closely with DP World," the spokesperson added.
The opposition Tories said the dispute showed that Labour ministers did not understand business.
"On the eve of this much-vaunted inward investment event, this is a body blow for the government," the party's business spokesperson Kevin Hollinrake said.
UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.
Investment gap
Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.
Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.
Richard Torbett, ABPI Chief Executive, noted “The UK can lead globally in medicines and vaccines, unlocking billions in R&D investment and improving patient access but only if barriers are removed and innovation rewarded.”
The UK invests just 9% of healthcare spending in medicines, compared with 17% in Spain, and only 37% of new medicines are made fully available for their licensed indications, compared to 90% in Germany.
Expert reviews
Shailesh Solanki, executive editor of Pharmacy Business, pointed that “The government’s own review shows the sector is underfunded by about £2 billion per year. To make transformation a reality, this gap must be closed with clear plans for investment in people, premises and technology.”
The National Institute for Health and Care Excellence (NICE) cost-effectiveness threshold £20,000 to £30,000 per Quality-Adjusted Life Year (QALY) — has remained unchanged for over two decades, delaying or deterring new medicine launches. Raising it is viewed as vital to attracting foreign investment, expanding patient access, and maintaining the UK’s global standing in life sciences.
Guy Oliver, General Manager for Bristol Myers Squibb UK and Ireland, noted that " the current VPAG rate is leaving UK patients behind other countries, forcing cuts to NHS partnerships, clinical trials, and workforce despite government growth ambitions".
Reeves’ push for reform, supported by the ABPI’s Competitiveness Framework, underlines Britain’s intent to stay a leading hub for pharmaceutical innovation while ensuring NHS patients will gain faster access to new treatments.
By clicking the 'Subscribe’, you agree to receive our newsletter, marketing communications and industry
partners/sponsors sharing promotional product information via email and print communication from Garavi Gujarat
Publications Ltd and subsidiaries. You have the right to withdraw your consent at any time by clicking the
unsubscribe link in our emails. We will use your email address to personalize our communications and send you
relevant offers. Your data will be stored up to 30 days after unsubscribing.
Contact us at data@amg.biz to see how we manage and store your data.